Compositions and methods for inhibiting gene expression of factor XII
AssigneeArrowhead Pharmaceuticals, Inc.
InventorsSteven B. Kanner, David L. Lewis, Darren H. Wakefield, Lauren J. Almeida
Life of this patent
Estimating the term…
Abstract
RNA interference (RNAi) triggers for inhibiting the expression of Factor XII (F12) gene through the mechanism of RNA interference are described. Pharmaceutical compositions comprising one or more F12 RNAi triggers together with one or more excipients capable of delivering the RNAi trigger(s) to a liver cell in vivo are also described. Delivery of the F12 RNAi trigger(s) to liver cells in vivo provides for inhibition of F12 gene expression and treatment of angioedema, including hereditary angioedema (HAE) and venous thromboembolism (VTE), and diseases associated with angioedema.
Claims25
An RNA interference (RNAi) trigger for inhibiting the expression of a Factor XII (F12) gene, wherein the RNAi trigger comprises a sense strand and an antisense strand, the antisense strand comprises nucleotides 2 to 19 (5′ to 3′) of SEQ ID NO:1417 (GGUCUUUCACUUUCUUGG), and wherein at least one nucleotide of the antisense strand is a modified nucleotide.
Dependencies are inferred from the claim text.